Results 13,161-13,180 of 26,685 for speaker:David Cullinane
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
David Cullinane: Mr. Breen is not in a position to do so.
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
David Cullinane: When will we know what that liability is or even get an estimate of it? Are we ever going to know?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
David Cullinane: When?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
David Cullinane: That was helpful. We will come back to the issue. I appreciate the point Mr. Breen is making but at the same time we are looking at what this will cost the State in overall terms and we would like some sense of what the liability will be. I can somewhat understand what Mr. Breen is saying, but it would be very helpful to us and the women involved to have some understanding of what the...
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
David Cullinane: Is Mr. Breen saying that in some cases the laboratory indemnifies the State for non-disclosure as well?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
David Cullinane: I am only asking about non-disclosure and the liability therefor.
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
David Cullinane: The Chair can pick up on this. My question concerned the liability of the State for non-disclosure, where we are not indemnified by the labs, what the estimated liability is and what the actual liability has been so far. Mr. Breen has given reasons that this information cannot be given to us, but we will come back to it. I want to return to the issue of breaking down the figures into...
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
David Cullinane: That is grand. We do not want to be unfair, and we do not want to create unfair difficulties for any clinician or give rise to any perception that might not reflect reality. We do not want a headline to say there is a problem in a hospital where there is not. I completely understand that. At the same time, we need some kind of metrics by which we can determine whether there is a problem....
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
David Cullinane: We will await the additional breakdown, on receipt of which we will examine it again. In his 2012 report the Comptroller and Auditor General examined the issue of legal costs. Page 36 of the 2016 annual report of the NTMA, details the cost of State Claims Agency claims resolved between 2012 and 2016. It shows that in 2016 the average total legal cost per clinical claim was...
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
David Cullinane: A cost that is five times greater appears to be a problem. The report also states that in 284 cases that were settled the total bill received from third parties was €49 million, with the actual cost being €27 million, giving a saving of 45%. Surely, if a saving of 45% was made, it suggests the bills coming in are hugely inflated.
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
David Cullinane: Okay. I have two questions for Mr. McCallion. The Scally report - it is an interesting report that I have read a few times - references a whole system failure, a systemic failure. Is it now accepted in the HSE that there was a systemic failure in regard to the issues that arose from the audit of CervicalCheck?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
David Cullinane: Dr. Scally uses the phrase "whole system failure".
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
David Cullinane: Mr. McCallion accepts that there was a whole system failure. What we are concerned about is the cost to the State and also the lessons learned. When did problems first arise? In what year did the HSE first become aware that there might be problems with the audit of smear tests?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
David Cullinane: Was it pre-2017?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
David Cullinane: Would Dr. Henry know?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
David Cullinane: The HSE was certainly aware of it in 2015.
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
David Cullinane: In 2015, 2016 and perhaps 2017 at many meetings of this committee we heard about discussions on a media strategy and disclosures. From our perspective, in terms of governance and procurement, what was most alarming about the Scally report was the finding that much of the original proposal material had been destroyed in 2017 and that it was in line with policy that after a particular...
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
David Cullinane: Looking forward is fantastic and I hope lessons have been learned. Looking back is primarily the core function of the committee. I appreciate that today in the main we are dealing with the claims issue, but the procurement issue is also important. The organisation knew from the findings of the audit that there were problems in procurement yet, when Dr. Scally tried to do his work, he was...
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
David Cullinane: It would be interesting to see how many claims were in play.
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
David Cullinane: I believe it cost more on the claimants’ side.